Risk factors of drug-induced diseases. Part 4. Medication errors and patient adherence


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Medication errors is another risk factor for drug-induced disease. According to the World Health Organization (WHO), there are several types of medication errors: prescribing errors, deteriorated drug error from compromised storage, drug utilization process error from the administration, dispensing, or monitoring. Medication errors not only lead to the development of adverse reactions, rise healthcare costs, but can also lead to life-threatening conditions and even deaths. The main risk factors for medication errors are mental health problems, including depression, cognitive impairment, asymptomatic or mildly symptomatic cases, the complexity, high cost of treatment, loss of patient trust. According to WHO, there are two groups of poor medication adherence: preventable (for example, if the patient does not understand instructions or forgets to take their medicine) and nonpreventable (for example, life-threatening side effects). Communication between the patient and healthcare professionals has a significant role. It is important to explain to the patient the need for treatment, the dose, frequency, duration of drug intake. And the doctor should take into account the patient’s financial opportunity, assess mental status, and the specialist also should explain the chosen treatment. Poor communication between the medical specialist and the patient reduces the effectiveness of pharmacotherapy and it is also one of the risk factors for the development of side effects and drug-induced diseases. Lack of adherence is directly related to the negative outcome in patients with diabetes mellitus, asthma, acquired immunodeficiency syndrome, organ transplants. For example, in hypertensive patients, lack of adherence leads to poor control of blood pressure, which can consequently result to stroke, heart attack, and kidney damage. Understanding the risk factors of medical adherence will help not only achieve clinical goals, but also diminish side effects, reduce hospitalizations, and avoid unnecessary healthcare expenses.

Толық мәтін

Рұқсат жабық

Авторлар туралы

D. Sychev

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

Olga Ostroumova

Russian Medical Academy of Continuing Professional Education

Email: ostroumova.olga@mail.ru
Dr. Sci. (Med.), Professor, Head of the Chair of Therapy and Polymorbid Diseases n.a. Academician M.S. Vovsi Moscow, Russia

A. Kochetkov

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

A. Pereverzev

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

M. Klepikova

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

E. Ebzeeva

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

V. De

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

Әдебиет тізімі

  1. Martin C.B., Hales C.M, Gu Q, Ogden C.L. Prescription Drug Use in the United States, 2015-2016. NCHS Data Brief. 2019;334:1-8. URLL https://www.cdc.gov/nchs/data/databriefs/db334-h.pdf Accessed October, 29, 2021
  2. Christensen L.D., Reilev M., Juul-Larsen H.G., et al. Use of prescription drugs in the older adult population-a nationwide pharmacoepidemiological study. Eur J Clin Pharmacol. 2019;75(8):1125-33. doi: 10.1007/s00228-019-02669-2.
  3. Решение Совета Евразийской экономической комиссии от 03.11.2016 №87 об «Утверждении Правил надлежащей практики фармаконадзора Евразийского экономического союза». URL: http://www.pharmvestnik.ru/images/files/823/eek87.pdf (ссылка активна на/ link active on 27.10.2021).
  4. Кузьмина А.В., Асецкая И.Л., Поливанов В.А., Зырянов С.К. Медицинские ошибки при применении лекарственных препаратов в практическом здравоохранении. Практическая пульмонология. 2016;(3):76-83.
  5. Brosch S. Good practice: MedDRA coding of case reports resulting in harm. Session 2 Reporting. European Medicines Agency Medication-errors workshop. London, 2013. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/03/WC500139872.pdf (accessed October, 27, 2021).
  6. Белоусов Ю.Б., Кукес В.Г, Лепахин В.К., Петров В.И. Клиническая фармакология. Национальное руководство. М., 2014. 976 с.
  7. Hartwig S.C., Denger S.D., Schneider PJ. Severity-indexed, incident report-based medication error-reporting program. Am J Hospital Pharm. 1991;48(12):2611-16.
  8. Holquist C. Medication errors: an FDA perspective. European Union Regulatory Workshop on Medication Errors, 2013. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/03/WC500139886.pdf (accessed October, 27, 2021).
  9. Kohn L.T., Corrigan J.M., Donaldson M.S. Human: Building a Safer Health System.Committee on Quality of Health Care in America. Institute of Medicine (US) To Err is Washington (DC): National Academies Press (US). 2000. 312 p. doi: 10.17226/9728.
  10. Jiménez Munioz A.B., Muino Miguez А., Rodriguez Pérez М.Р, et al. Medication error prevalence.Intern J Health Care Quality Assurance. 2010;23(3):328-38. doi: 10.1108/09526861011029389.
  11. Bates D.W., Cullen D.J., Laird N., et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. J Am Med Associat. 1995; 274(1):29-34.
  12. Keohane C.A., Bates D.W. Medication safety. Obst. Gynecol. Clin North Am. 2008;35(1):37-52 (viii). doi: 10.1016/j.ogc.2007.12.002.
  13. Bates D.W., Boyle D.L., Vander Vliet M.B., et al. Relationship between medication errors and adverse drug events. J General Int Med. 1995;10(4):199-205. doi: 10.1007/BF02600255.
  14. Budnitz D.S., Pollock D.A., Weidenbach K.N., et al. National surveillance of emergency department visits for outpatient adverse drug events. J Am Med Associat. 2006;296(15):1858-66. doi: 10.1001/jama.296.15.1858.
  15. Alqenae FA., Steinke D., Keers R.N. Prevalence and Nature of Medication Errors and Medication-Related Harm Following Discharge from Hospital to Community Settings: A Systematic Review. Drug Saf. 202;43(6):517-37. doi: 10.1007/s40264-020-00918-3.
  16. Лепахин В.К, Астахова А.В., Овчинникова Е.А., Овчинникова Л.К. Врачебные ошибки как причина осложнений лекарственной терапии. Качественная клиническая практика. 2002;(1):71-7.
  17. Karthikeyan M., Balasubramanian T., Khaleel M.i., et al. A Systematic Review on Medication Errors.intern. J Drug Develop Res. 2015;7(4):9-11.
  18. Carney S.L. Medication accuracy and general practitioner referral letters.intern Med J. 2006;36(2):132-33. doi: 10.1111/j.1445-5994.2006.01022.x.
  19. Berman A. Reducing medication errors through naming, labeling, and packaging. J Med Syst. 2004;28(1):9-29. doi: 10.1023/b:jo ms.0000021518.60670.10.
  20. Аляутдин РН, Переверзев А.П., Романов Б.К., Бунятян Н.Д. Квопросу о влиянии названий и маркировки лекарственных средств на риск развития медицинских ошибок. Безопасность и риск фармакотерапии. 2014;3(4):15-9.
  21. Manias E., Kusljic S., Wu A.interventions to reduce medication errors in adult medical and surgical settings: a systematic review. Ther Adv Drug Saf. 2020;11:2042098620968309. doi: 10.1177/2042098620968309.
  22. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97. doi: 10.1056/NEJMra050100.
  23. Simon S.T., Kini V., Levy A.E., Ho P.M. Medication adherence in cardiovascular medicine. BMJ. 2021;374:n1493. doi: 10.1136/bmj.n1493.
  24. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. 209 р. URL: http://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf;jsessionid=F862E0706A2A09D12582B472D248F202?sequence=1 (accessed 29.10.202)1.
  25. Bailey R., English J., Knee C., Keller A. Treatment Adherence in integrative Medicine-Part One: Review of Literature.integr. Med. (Encinitas). 2021;20(3):48-60.
  26. Burnier M. is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence. Front Pharmacol. 2019;9:1540. doi: 10.3389/fphar. 2018.01540.
  27. Jin J., Sklar G.E., Min Sen Oh V., Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-86. doi: 10.2147/tcrm.s1458.
  28. Drotar D. (ed.). Promoting Adherence to Medical Treatment in Chronic Childhood illness: Concepts, Methods, and interventions. Psychology Press, 2000. 544 р.
  29. Ashton Acton Q. issues in Pharmacology, Pharmacy, Drug Research, and Drug innovation. ScholarlyEditions, 2012. 4229 p.
  30. Wu J.Y, ieung W.Y., Chang S., et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ. 2006;333(7567):522. doi: 10.1136/bmj.38905.447118.2F.
  31. Bosworth H.B., Granger B.B., Mendys P, et al. Medication adherence: a call for action. Am Heart J. 2011;162(3):412-24. doi: 10.1016/j.ahj.2011.06.007.
  32. Tisdale J.E., Miller D.A. (ed.). Drug induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists, 2018. 1399 p.
  33. Marcum Z.A., Sevick M.A., Handler S.M. Medication nonadherence: a diagnosable and treatable medical condition. JAMA. 2013;309(20):2105-106. doi: 10.1001/jama.2013.4638.
  34. Sabate E. Adherence to Long-term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization. 2003. URL: https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1 (accessed 28.10.2021).
  35. Tomaszewski M., White C., Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855-61. doi: 10.1136/heartjnl-2013-305063 PMID: 24694797.
  36. Zedier B.K., Kakad P, Colilla S., et al. Does packaging with a calendar feature improve adherence to selfadministered medication for long-term use? A systematic review. Clin Ther. 2011;33(1):62-73. doi: 10.1016/j.clinthera.2011.02.003.
  37. Flaynes R.B., Ackloo E., Sahota N., et al.interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008(2):CD000011. doi: 10.1002/14651858.CD000011.pub3.
  38. Anderson L.J., Nuckols T.K., Coles C., et al. Members of the PHARM-DC Group. A systematic overview of systematic reviews evaluating medication adherence interventions. Am J Health-System Pharm. 2020;77(2):138-47. doi: 10.1093/ajhp/zxz284.
  39. Bryant J., McDonald V.M., Boyes A., et al. improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir. Res. 2013;14(1):109. doi: 10.1186/1465-992114-109.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>